Bureau Veritas Acquires Security Innovation Inc. to Reinforce Its Cybersecurity Expertise in the Software Domain

PARIS - Thursday, 25. July 2024

(BUSINESS WIRE)--Bureau Veritas, a global leader in the Testing, Inspection and Certification (TIC) industry, announces today it has signed an agreement to acquire Security Innovation Inc., a US-based specialized software security firm. This acquisition is aligned with Bureau Veritas LEAP | 28 strategy to accelerate growth in cybersecurity, a fast-growing strategic sector, and to create a new stronghold.

Security Innovation will expand Bureau Veritas's client portfolio and will establish a new cybersecurity hub for its clients in the US with the opportunity to scale it globally. Founded in 2002 and headquartered in Boston with offices in Seattle and Pune (India), Security Innovation Inc. provides state-of-the-art software security consulting and services focused on software testing, Secure Software Development Lifecycle (SDLC) advisory, and training. The company has a proven track record of successfully addressing large private and public organizations’ software security services and is a recognized player in the US market. This acquisition will add a strong network of 95 highly skilled specialists to Bureau Veritas. Security Innovation generated EUR 21 million in revenue in 2023.

“This acquisition reinforces our position in the fast-growing cybersecurity market and is a key addition to our existing portfolio with a focus on North America. It complements our capabilities and will generate synergies to the benefit of our customers. This is a fantastic opportunity to ramp up our existing cybersecurity testing expertise and develop our AI/Large Language Model (LLM) capabilities, positioning Bureau Veritas as the TIC leader of cybersecurity technology innovations. I warmly welcome all new colleagues from Security Innovation to Bureau Veritas.” said Hinda Gharbi, Chief Executive Officer at Bureau Veritas.

“This strategic move will enable our customers to benefit from Bureau Veritas’ extensive expertise in the TIC sector, global presence, and its undisputable reputation as a trusted third party. For Security Innovation teams, this is a unique opportunity to join a globally recognized network of experts and to benefit from professional opportunities and career development on the scale of an international Group such as Bureau Veritas. We look forward to the next steps in our journey together” comments Ed Adams, CEO of Security Innovation Inc.

The closing of this transaction is expected to take place in Q3 2024.

***

About Bureau Veritas

Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress.

With a vision to be the preferred partner for its customers’ excellence and sustainability, the company innovates to help them navigate change.

Created in 1828, Bureau Veritas’ 83,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.

Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.

For more information, visit www.bureauveritas.com, and follow us on Twitter (@bureauveritas) and LinkedIn.

Our information is certified with blockchain technology.

Check that this press release is genuine at www.wiztrust.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725291794/en/

Permalink

https://www.aetoswire.com/en/news/2507202440557

Contacts

ANALYST/INVESTOR CONTACTS

Laurent Brunelle

+33 (0)1 55 24 76 09

laurent.brunelle@bureauveritas.com

Colin Verbrugghe

+33 (0)1 55 24 77 80

colin.verbrugghe@bureauveritas.com

Karine Ansart

+33 (0)1 55 24 76 19

karine.ansart@bureauveritas.com

MEDIA CONTACTS

Anette Rey

+33 (0)6 69 79 84 88

anette.rey@bureauveritas.com

Martin Bovo

+33 (0) 6 14 46 79 94

martin.bovo@bureauveritas.com

Quectel Unveils Industry-First Quad-Band GNSS Module, Expanding Comprehensive GNSS Solutions Portfolio

 BELGRADE, Serbia - Thursday, 25. July 2024

(BUSINESS WIRE) -- Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the LG290P, the first quad-band GNSS module, designed to deliver high performance for the most demanding applications, ensuring exceptional RTK availability and quality even in challenging environments. Providing the instantaneous centimeter-level accuracy needed to ensure the precision required for applications such as precision agriculture, robotic lawn mowers, surveying and personal robots, the module also delivers superior coverage that supports base stations from greater distances, ensuring reliable performance.

The introduction of the LG290P module expands Quectel's range of high-accuracy, RTK-capable GNSS modules. This range includes the dual-band industrial-grade LC29H, the automotive-grade LG69T, and now the quad-band LG290P, providing users with a selection of GNSS modules to cover a wide variety of applications.

Future-proofing applications by supporting all constellations including GPS, GLONASS, Galileo, BDS, NavIC, QZSS, as well as SBAS support (WASS, EGNOS, MSAS, and GAGAN) and advanced satellite-based signals such as PPP-B2b, CLAS (QZSS L6), Galileo HAS E6, the LG290P is a cost-effective industrial-grade module that receives L1, L2, L5 and E6 frequency bands.

In addition, the LG290P is compatible with Quectel triple band RTK Services and ensures superior coverage that supports base stations from greater distances, ensuring stable and reliable performance in the most difficult urban environments, making it exceptionally well suited for sectors such as autonomous lawnmowers, delivery robots, surveying and precision agriculture. The quad-band solution can enhance the RTK fix rate by 50% compared to dual band in extremely challenging environments, such as a garden encircled by trees and walls. Additionally, it can reduce the time to achieve RTK fix to less than five seconds, in contrast to the ten to fifteen seconds required by the dual band solution.

“Introducing the quad-band GNSS Module to the market represents our commitment to advancing technology and providing our customers with the most reliable and accurate navigation solutions available,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We believe this product will be a game-changer in many fields, enabling new possibilities and improving efficiencies and precise location.”

The module supports an advanced multi-frequency RTK algorithm, ensuring rapid and reliable RTK high-precision positioning results even in challenging conditions such as under dense tree cover, alongside buildings or inside urban canyons. With advanced anti-interference technology, the LG290P incorporates a professional-grade interference signal detection and Narrowband Interference Canceller (NIC), significantly enhancing signal reception performance in complex electromagnetic environments. Moreover, supporting integrity monitoring and authentication information verification, the LG290P aids automatic navigation systems in making control decisions, particularly fitting for critical applications like autonomous vehicles and lawnmowers.

The LG290P excels in terms of security by incorporating on-chip ECC check and Secure Boot for firmware protection. Measuring a compact 12.2 mm × 16.0 mm × 2.6 mm, the LG290P is the smallest quad-band module available, offering greater design flexibility for customers, reducing integration challenges, and enabling compact designs for a wide array of precision products.

Customers are also able to streamline their design process by sourcing the appropriate antenna for this module, ensuring flexibility and compatibility for diverse project requirements.

The LG290P quad band GNSS module is now available to order through the Quectel website and distributors.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,600 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725061807/en/

Permalink

https://www.aetoswire.com/en/news/2507202440539

Contacts

Media: media@quectel.com

 

PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance

  ZUG, Switzerland - Thursday, 25. July 2024 AETOSWire 

Detailed results from the phase III ARCADIA 1 and 2 trials evaluating the safety and efficacy of nemolizumab in atopic dermatitis were published for the first time in The Lancet1

Data from this phase III program demonstrate the potential of nemolizumab (in combination with background therapy) to improve key aspects of atopic dermatitis; skin lesions, itch, and sleep disturbance in adolescent and adult patients with moderate-to-severe atopic dermatitis1

In the ARCADIA trials, statistically significant improvements in itch were observed as early as one week after nemolizumab treatment initiation1

Nemolizumab is a first-in-class monoclonal antibody that inhibits the signaling of IL-31, a neuroimmune cytokine known to drive key signs and symptoms of atopic dermatitis2-5

 

(BUSINESS WIRE) -- Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet.1The trials evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without topical calcineurin inhibitors (TCI), versus placebo in combination with TCS, with or without TCI, in adolescent and adult patients with moderate-to-severe atopic dermatitis.1 Results show that the trials met their co-primary and all key secondary endpoints, showing that nemolizumab significantly improved skin lesions, itch and sleep disturbance by Week 16 when compared to placebo, with significant itch relief observed as early as Week 1.1

 

“Publication of the phase III ARCADIA program results for the first time in The Lancet reinforces both the robustness of our trial design and the potential of nemolizumab as an effective treatment option for patients living with atopic dermatitis. We are working closely with regulators in the U.S., Europe, and elsewhere to bring nemolizumab to those in need as soon as possible.”

 

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.

GLOBAL HEAD OF R&D

GALDERMA

 

 

The phase III ARCADIA 1 and 2 trials enrolled 1,728 adolescent and adult patients with moderate-to-severe atopic dermatitis.1 Results demonstrated that patients treated with nemolizumab, administered subcutaneously every four weeks in combination with TCS, with or without TCI, showed statistically significant improvements in both co-primary endpoints, when compared to placebo in combination with TCS, with or without TCI, after 16 weeks of treatment:1

36% and 38% of nemolizumab-treated patients in ARCADIA 1 and 2 achieved clear skin, defined by an investigator’s global assessment score of clear (0) or almost-clear (1), when compared to the placebo group (25% and 26%, respectively; p<0.001).

44% and 42% of nemolizumab-treated patients in ARCADIA 1 and 2 achieved at least a 75% improvement in the eczema area and severity index score, when compared to the placebo group (29% and 30%, respectively; p<0.001).

The trials also met all key secondary endpoints confirming rapid responses on itch, and statistically significant improvements in sleep disturbance with nemolizumab in combination with TCS, with or without TCI, when compared to placebo in combination with TCS, with or without TCI:1

Clinically meaningful improvements in itch were observed as early as one week after nemolizumab treatment initiation when compared to placebo.

An itch-free or nearly itch-free state (defined as a score of <2 on the peak pruritus numerical rating scale) was achieved by 16% of patients in both ARCADIA 1 and 2 at Week 4, after just one dose of nemolizumab, when compared to the placebo group (4% and 3%, respectively; p<0.001).

At Week 16, 38% and 34% of nemolizumab-treated patients in ARCADIA 1 and 2 achieved at least a four-point improvement in the sleep disturbance numerical rating scale, when compared to the placebo group (20% and 16%, respectively; p<0.001).

The safety profile was consistent between nemolizumab and placebo groups; most treatment-emergent adverse events were non-serious, and of mild-to-moderate severity.1

Nemolizumab is a first-in-class monoclonal antibody specifically designed to target the interleukin-31 (IL-31) receptor alpha and inhibit IL-31 signaling.2 In atopic dermatitis, IL-31 drives itch and is involved in inflammation and skin barrier disruption.3-5

 

“As a practicing dermatologist, I’m excited about the potential of nemolizumab for atopic dermatitis patients. These phase III data demonstrate that, by blocking the activity of IL-31, nemolizumab could effectively address itch, skin lesions and sleep disturbance. Many patients complain that chronic itch negatively impacts their overall quality of life. Reducing itch within just one week of treatment could significantly ease the burden of disease.”

 

Prof. Jonathan Silverberg

LEAD INVESTIGATOR OF THE ARCADIA CLINICAL PROGRAM,

Professor of Dermatology, George Washington University

School of Medicine and Health Sciences, United States

 

 

Based on the results of the ARCADIA 1 and 2 trials, the U.S. Food and Drug Administration accepted for review Galderma’s Biologics License Application for nemolizumab for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis, with a decision expected by the end of the year.6 Galderma is awaiting decisions from several other regulatory authorities on its filing applications for both atopic dermatitis and prurigo nodularis, including the European Medicines Agency, Health Canada, and the Access Consortium.7 Regulatory submissions to other healthcare authorities around the world are ongoing.

Media can find more information about atopic dermatitis in this media toolkit page.

About atopic dermatitis

Atopic dermatitis a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions.4,8,9 It affects more than 230 million people worldwide and is the most common inflammatory skin disease, impacting almost four times more people than psoriasis.4,10 While currently available treatments for atopic dermatitis show some improvements of signs and symptoms, not all patients experience itch relief and clear skin to the same degree, and many do not respond optimally to approved therapies.4,11

About nemolizumab

Nemolizumab is a monoclonal antibody developed by Galderma and is the first therapy designed to specifically inhibit interleukin-31 (IL-31) cytokine signaling.2 IL-31 signaling is known to drive the most burdensome symptom for people with atopic dermatitis and prurigo nodularis – itch.3-5

Nemolizumab is under review for both prurigo nodularis and atopic dermatitis by several regulatory authorities worldwide, including the U.S. Food and Drug Administration, European Medicines Agency and in Australia, Singapore, Switzerland, and the United Kingdom via the Access Consortium, with ongoing submissions in additional countries.6,7

Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd., and subsequently licensed to Galderma in 2016 worldwide – except Japan and Taiwan. In Japan, nemolizumab is approved for the treatment of pruritus associated with atopic dermatitis and for prurigo nodularis.12,13

About the ARCADIA clinical trial program1,14,15

The ARCADIA program included two identically designed, pivotal phase III clinical trials, which enrolled more than 1,700 patients – ARCADIA 1 and ARCADIA 2.

These global, randomized, multicenter, double-blind, placebo-controlled phase III clinical trials, evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks compared to placebo (both administered with background topical corticosteroids with or without topical calcineurin inhibitors).

The trials were conducted in adolescent and adult patients (12 years and over) with moderate-to-severe atopic dermatitis for an initial treatment phase of 16 weeks. Patients who responded to treatment (defined as patients who achieved an investigator’s global assessment score of clear (0) or almost clear (1), or a 75% or greater improvement in the eczema area and severity index score) were then re-randomized to a maintenance treatment phase for up to 48 weeks.

About Galderma

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com

References:

Silverberg JI, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 & 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024. doi: 10.1016/S0140-6736(24)01203-0

Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi:10.1016/j.jaci.2019.08.013

Bağci IS and Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3):P858-866. doi: 10.1016/j.jaci.2017.10.045

Langan SM, Irvine AD, Weidinger S. Atopic dermatitis [published correction appears in Lancet. 2020;396(10253):758]. Lancet. 2020;396(10247):345-360. doi: 10.1016/S0140- 6736(20)31286-1

Datsi A, et al. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 2021;76:2982-2997. doi: 10.1016/j.jaard.2020.04.183

Galderma. Galderma announces regulatory filing acceptance for nemolizumab in prurigo nodularis and atopic dermatitis in the U.S. and EU. Available online. Last accessed July 2024

Galderma. Galderma receives filing acceptance for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries. Available online. Last accessed July 2024

Yang G, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8): 2867. doi: https://doi.org/10.3390/ijms21082867

Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi: 10.1056/NEJMra2023911

Raharja A, et al. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170-173. doi: 10.7861/clinmed.2021-0257

Lobefaro F, et al. Atopic dermatitis: Clinical aspects and unmet needs. Biomedicines. 2022;102927. doi: 10.3390/biomedicines10112927

Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Last accessed July 2024

Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Last accessed July 2024

ClinicalTrials.Gov. Efficacy & Safety of Nemolizumab in Subjects With Moderate- to-Severe Atopic Dermatitis (NCT03989349). Available online. Last accessed July 2024

ClinicalTrials.Gov. Efficacy & Safety of Nemolizumab in Subjects With Moderate- to-Severe Atopic Dermatitis (NCT03985943). Available online. Last accessed July 2024

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724817366/en/

Permalink

https://www.aetoswire.com/en/news/2507202440532

Contacts

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Sébastien Cros

Corporate Communications Director

sebastien.cros@galderma.com

+41 79 529 59 85

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

 

Global Innovation to Take Center Stage at the First World Technology Games in 2026 – A Competition, Festival & Leadership Summit to Celebrate Human Ingenuity

PARIS, France - Thursday, 25. July 2024

Global Esports Federation, Indy Autonomous Challenge and Other Leading Organizations to Support Flagship Competition

Inaugural Host City Selection and Corporate Partner Development Begins

Assets Linked HERE


(BUSINESS WIRE)--The World Technology Games (WTG), a groundbreaking global competition in innovation, technology and science, announced its inaugural event for Q3 2026. The annual, five-day event will include Competitions, a Festival and a Leadership Summit. The Games will celebrate and elevate advancements across Life, Earth, Data and Industrial Sciences, through unifying themes like sustainability and AI.

“We built the World Technology Games to inspire people around the world to create technological solutions for today’s most formidable challenges,” said Alexander Brown, CEO of the World Technology Games. “Our first-of-its-kind international event will convene brilliant minds from diverse backgrounds to compete, collaborate, and catalyze change at global scale.”

The World Technology Games were showcased by Mr. Brown at the UNESCO “Change the Game” Global Sport Conference as France hosts the 2024 Olympic Games. The WTG underscored its commitment to support key UN Sustainable Development Goals and to UNESCO’s vision of building multilateral collaboration on education, science, culture, communication and information.

The WTG will honor the ambition, competitive spirit and ingenuity that drive today’s greatest technological contributions. An international cohort of scientists, engineers and innovators will unite for two categories of cutting-edge competitions that aim to entertain and empower people through technology, passion and purpose. “Spotlights” are organized in partnership with established leagues, including support from the Indy Autonomous Challenge and the Global Esports Federation. Unique to the Games, “Originals” are characterized by scientific rigor, real-world application and technological acumen, including culinary creativity, sustainable fashion design, robotics and more.

Through the live event and digital content, the WTG targets a global audience of more than 1.6 billion people who consider technology an essential component of their daily lives. With a focus on engaging Gen T – the nearly 700 million individuals globally who are poised to shape the future of technology – the Games will be amplified by a multi-channel approach distributed across social, digital, podcasts, streaming platforms and linear broadcast.

The WTG is led by Alexander Brown. Mr. Brown has a proven track record of building and growing businesses at a global scale including serving as Managing Director of ESPN Asia and ESPN Star Sports, as well as leadership positions with the NBA, Univision and One World Sports. Brown also served as President & CEO of CNBC Asia. Chairman of the Board, Paul J. Foster is CEO & Member of the Board for the Global Esports Federation and focuses on integrating innovative technology with social impact. He brings more than 20 years of experience in the Olympic Movement, an extensive tenure at the International Olympic Committee and global strategic consulting. The WTG is championed by an International Advisory Council of multidisciplinary experts from more than 20 countries who have spearheaded the growth of global companies and organizations across science, technology, diplomacy, entertainment, and finance.

The Games will also feature an immersive festival and thought leadership summit. The World Technology Festival will celebrate the intersection of technology, art and culture through exhibitions, product showcases and workshops. The World Technology Summit will convene industry experts with keynote speeches, debates and expert panels to explore future trends and the transformative potential of technology.

The inaugural host city selection has begun, with cities worldwide encouraged to submit expressions of interest through September 2024. For more information on the World Technology Games please visit: https://worldtechnology.games/.

About the World Technology Games:

The World Technology Games (WTG) is a global, first-of-its-kind competition celebrating human ingenuity in Life, Earth, Data and Industrial sciences. Set to debut in 2026, the annual five-day event will convene scientists, engineers and innovators from around the world for a series of cutting-edge competitions, a festival and a leadership summit that address humanity’s greatest challenges through technology, passion and purpose. Led by an accomplished leadership team of global multidisciplinary experts, the WTG will empower and entertain a worldwide audience by honoring the unheralded, yet brilliant minds behind today’s greatest advancements.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240725287146/en/

Permalink
https://www.aetoswire.com/en/news/2507202440548

Contacts

Media Inquiries:
Hustle&Co. / JSA+Partners
WorldTechGamesPR@hustleandco.com

Information, Sponsorship, & Host City Inquiries:
World Technology Games Secretariat
mlucic@worldtechnology.games

KAGA FEI Develops EC4L15BA1 Bluetooth Low Energy Module Balancing Low Power Consumption with High Processing Capability

 YOKOHAMA, Japan - Thursday, 25. July 2024

(BUSINESS WIRE)--KAGA FEI Co., Ltd., a global provider of leading short distance wireless modules, announced today the EC4L15BA1 Bluetooth Low Energy module. The module has a built-in antenna and has obtained various certifications. Consequently, it reduces the development time and certification costs for next-generation wireless IoT products such as industrial IoT, medical/healthcare products, and sports/fitness sensors, enabling faster time-to-market.

Furthermore, it supports PSA*1 certification, making it easier to develop IoT devices that meet advanced security requirements. Mass production is scheduled to begin in June 2025. The Company will continue to respond to market needs and expand its product lineup.

Product Features

1. Low Power Consumption

The module is equipped with components for low-power operation, and the power consumption required for communication is significantly reduced. For example, the receive current is about half that of the EC2832AA2 module equipped with nRF52832.

2. High Processing Capability, Advanced Security Level

The module includes a 128MHz Arm Cortex-M33 processor, 1.5MB of non-volatile memory, and 256KB RAM, achieving over twice the processing capability of the EC2832AA2. Moreover, the PSA Level 3 certification ensures that it meets the highest security needs.

3. Multi-Protocol

It supports not only Bluetooth Low Energy, but also Thread and Matter standard*2. Furthermore, it can communicate using a proprietary 4Mbps mode.

4. Built-in Antenna and Pre-Certified

Features a built-in antenna, eliminating the need for antenna design. It has obtained Bluetooth qualification and certifications for Radio Law MIC (Japan), FCC (USA), and ISED (Canada), reducing the time and costs.

Product Availability

Sample : November 2024

Start of mass production : June 2025

About Trademarks

The product names and other proper nouns mentioned herein are trademarks or registered trademarks of their respective companies.

*1. PSA: PSA (Platform Security Architecture) is a certification scheme led by Arm. Level 3 is the highest level of certification for protecting IoT devices from physical and software attacks.

*2. Matter standard: A smart home standard developed by the Connectivity Standards Alliance (CSA) to promote interoperability between smart home devices and IoT platforms from different manufacturers.

KAGA FEI website

https://www.kagafei.com/jp/eng/

Disclaimer

Product specifications, service content, etc. stated in the news release are as of the date of announcement and is subject to change without notice.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240708389105/en/

Permalink

https://aetoswire.com/en/news/2507202440552

Contacts

KAGA FEI Co., Ltd.

Solution Business Headquarters

Module Products Division

Email: ml-module_contact@jp.kagafei.com

Corpay Cross-Border Named the Official World Athletics Foreign Exchange Supplier

TORONTO - Thursday, 25. July 2024

Providing access to currency risk management and cross-border payments solutions

(BUSINESS WIRE)--Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with World Athletics, the international governing body for the sport of athletics, covering track and field, cross country running, road running, race walking, mountain running, and ultra running, to become their Official Foreign Exchange (FX) Supplier.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724239669/en/

Through this partnership, World Athletics, and the broader World Athletics family** Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. Additionally, Corpay Cross-Border’s award-winning platform will enable them to manage their global payments from a single point of access.

“Corpay Cross-Border is very honoured to join the World Athletics family as their Official Foreign Exchange Supplier,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “I am confident that World Athletics and the broader World Athletics family, including their federation members and partners will benefit from access to our comprehensive currency risk management and cross-border payments solutions, along with our extensive experience gained within the world of sports.

“We are pleased to welcome Corpay Cross-Border as an Official Supplier to World Athletics,” said World Athletics President Sebastian Coe. “World Athletics receives the majority of its income in USD but makes substantial payments each year in various currencies. Having the expertise of Corpay Cross-Border, with access to currency risk management and cross-border payments solutions, will prove invaluable.”

About Corpay

Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Corpay’s suite of modern payment solutions help its customers better manage vehicle-related expenses (such as fueling and parking), travel expenses (e.g. hotel bookings) and payables (e.g. paying vendors). This results in our customers saving time and ultimately spending less. Corpay Cross-Border refers to a group of legal entities owned and operated by Corpay, Inc.

Corpay – Payments made easy. To learn more visit www.corpay.com.

*“Corpay” in this document primarily refers to the Cross-Border Division of Corpay, Inc. https://www.corpay.com/cross-border; a full listing of the companies that are part of Corpay Cross-Border is available here: https://www.corpay.com/compliance.

** Subject to credit and compliance approval from the relevant Corpay company.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724239669/en/

Permalink

https://www.aetoswire.com/en/news/2507202440547

Contacts

Corpay Contact:

Brad Loder

Chief Marketing Officer

Corpay Cross-Border Solutions

+1 (647) 627-6635

brad.loder@corpay.com

SLB announces voluntary delisting from Euronext Paris

  (BUSINESS WIRE) -- Regulatory News:

SLB (NYSE: SLB) today announced that it will proceed with a voluntary delisting of its shares (ISIN: AN8068571086) from Euronext Paris.

Consistent with its prior decisions to delist from other exchanges, SLB reviewed the low trading volumes on the Euronext Paris and, given the increasing costs, administrative requirements and managerial time required to maintain a dual listing, has requested a voluntary delisting from the Euronext Paris.

SLB became a public company in 1962 with its orignal listing on the New York Stock Exchange (NYSE), which has been its primary exchange. SLB will maintain its single listing on NYSE under the symbol “SLB”.

The delisting has been approved by the Board of Directors of Euronext Paris and the company’s shares will remain listed on the NYSE under the symbol “SLB”.

The holders of SLB shares traded on Euronext and held through the facilities of Euroclear France (the “SLB Euronext Shares”) will have the following options:

• keep their SLB Euronext Shares, which they will be able to trade on Euronext Paris until the day before the delisting date and on the NYSE thereafter through the facilities of The Depositary Trust Company (“DTC”), subject to the terms applied by their financial intermediary and their custody arrangements; or

• participate in a voluntary sales facility (described below) to sell all or part of their SLB Euronext Shares, in accordance with the rules and regulations of Euronext Paris.

For the avoidance of doubt, holders of SLB Euronext Shares will be able to trade on Euronext Paris until August 16, 2024 (the last trading date prior to the delisting).

Procedure of the Voluntary Sales Facility

Shareholders who wish to sell their SLB Euronext Shares utilizing the voluntary sales facility should request that their financial intermediaries deliver their SLB Euronext Shares to Uptevia, acting as centralizing agent, at any time from July 29, 2024, to August 12, 2024 (inclusive).

SLB Euronext Shares delivered to Uptevia will be sold on the NYSE as from August 15, 2024, at the market price prevailing at the time of sale.

Uptevia will calculate the average sales price of SLB Euronext Shares sold during the sales period and transfer the sale proceeds (which will be converted into euros from U.S. dollars by Uptevia) to the participating shareholders once it receives the funds.

The company will pay the fees for the centralization and the brokerage fee related to the sale of SLB Euronext Shares delivered to Uptevia as part of the voluntary sales facility.

This voluntary sales facility procedure is also described in a Euronext notice to be published on July 25, 2024.

Please note that no guarantee can be given by the company or by Uptevia as to the price at which the SLB Euronext Shares tendered pursuant to the voluntary sales facility will actually be sold. This process is being provided solely as an accommodation to holders of SLB Euronext Shares.

Shareholders may decide not to participate in the voluntary sales facility or may decide not to take any action, in which case no guarantee can be given to them on the terms that will be applied by their financial intermediary after the delisting. Shareholders are urged to consult their own investment advisors before making a decision to participate or not in this process.

The calendar of the voluntary sales facility and the delisting of the company described above is summarized as follows (it being specified that the company reserves the right to amend this calendar):

Event	Date
Voluntary Sales Facility
Beginning of the voluntary sales facility	July 29, 2024
End of the voluntary sales facility	August 12, 2024
End of the centralization by Uptevia	August 14, 2024 (before 4:00 PM Paris time)
Sale on the NYSE of the shares tendered in the voluntary sales facility	Beginning August 15, 2024
Settlement of the proceeds of the sale to the relevant financial institutions	As soon as possible after receipt of the proceeds of the sale
Delisting
Last day of trading of the company’s shares on Euronext Paris	August 16, 2024
Delisting of SLB Euronext Shares on Euronext Paris	August 19, 2024

Shareholders participating in the voluntary sales facility are reminded that they acknowledge and accept the risks related to the change in the share market price and/or applicable foreign exchange rates between the date on which their shares are delivered to Uptevia for participation in the voluntary sales facility and the receipt of the applicable average sale proceeds. All tenders of SLB Euronext Shares under the voluntary sales facility will be irrevocable.

Shareholders who would like additional information about the voluntary sales facility or the delisting procedure may contact their custodian and usual financial intermediary, who has received the details of the delisting or the company by email at investor-relations@slb.com.

About SLB

SLB (NYSE: SLB) is a global technology company that drives energy innovation for a balanced planet. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724224924/en/

Permalink
https://aetoswire.com/en/news/2507202440530

Contacts

Media
Moira Duff – Director of External Communications
SLB
Tel: +1 (713) 375-3407
media@slb.com

Investors
James R. McDonald – SVP of Investor Relations & Industry Affairs
Joy V. Domingo – Director of Investor Relations
SLB
Tel: +1 (713) 375-3535
investor-relations@slb.com